CervoMed's Neflamapimod Approved for ALS Trials
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 18 2026
0mins
Should l Buy CRVO?
Source: Newsfilter
- Trial Launch: CervoMed's Neflamapimod has been included in the EXPERTS-ALS platform, with the first ALS patient expected to be dosed by the end of 2026, marking a significant advancement in treatments for neurodegenerative diseases.
- Funding Support: The trial costs are funded by the UK National Institute for Health and Care Research and leading motor neuron disease charities, highlighting the commitment to ALS research and support.
- Efficacy Assessment: Neflamapimod will be evaluated in approximately 35 ALS patients over 18-24 weeks, focusing on its impact on the neurodegeneration biomarker NfL, with potential further evaluation expanding to 80 patients.
- Scientific Rationale: Neflamapimod selectively inhibits p38 MAP kinase to reduce neurotoxicity, demonstrating a favorable safety and efficacy profile, potentially offering new treatment hope for ALS patients.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRVO
Wall Street analysts forecast CRVO stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.540
Low
19.00
Averages
22.75
High
27.00
Current: 4.540
Low
19.00
Averages
22.75
High
27.00
About CRVO
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CervoMed Advances Neflamapimod in Phase 3 Trial for Dementia
- Dose Selection: CervoMed has selected a dosing regimen of 50mg of neflamapimod three times daily for its planned Phase 3 trial to ensure plasma drug concentrations align with those of the clinically effective drug product, thereby enhancing therapeutic efficacy and patient response.
- Manufacturing Process Improvement: The company has developed a new controlled manufacturing process that exclusively produces a stable crystal form of neflamapimod, addressing previous issues with multiple solid-state forms that led to decreased bioavailability, thus improving drug efficacy and safety.
- Clinical Trial Results: In the Phase 2b RewinD-LB trial, neflamapimod demonstrated significant potential to improve cognitive and functional outcomes, particularly in patients without Alzheimer's disease co-pathology, further supporting its scientific validity as a treatment candidate for DLB.
- Future Development Plans: CervoMed plans to initiate a pivotal global Phase 3 trial in the second half of 2026, focusing on DLB patients without AD co-pathology, indicating the company's long-term commitment to this field and highlighting its need for funding.
See More
CervoMed's Neflamapimod Approved for ALS Trials
- Trial Launch: CervoMed's Neflamapimod has been included in the EXPERTS-ALS platform, with the first ALS patient expected to be dosed by the end of 2026, marking a significant advancement in treatments for neurodegenerative diseases.
- Funding Support: The trial costs are funded by the UK National Institute for Health and Care Research and leading motor neuron disease charities, highlighting the commitment to ALS research and support.
- Efficacy Assessment: Neflamapimod will be evaluated in approximately 35 ALS patients over 18-24 weeks, focusing on its impact on the neurodegeneration biomarker NfL, with potential further evaluation expanding to 80 patients.
- Scientific Rationale: Neflamapimod selectively inhibits p38 MAP kinase to reduce neurotoxicity, demonstrating a favorable safety and efficacy profile, potentially offering new treatment hope for ALS patients.
See More
Biotech Insider Buying Signals Strong, Three Companies Draw Attention
- Insider Buying Signals: Summit Therapeutics has recently seen insider purchases, indicating management's confidence in its cancer drug's market potential, which could lead to significant stock price volatility in the future.
- Neurological Drug Development: Annexon also reported insider buying, reflecting confidence in its antibody drugs targeting neurological diseases, despite the high clinical trial risks, the potential for success is substantial.
- Cognitive Disorder Treatment: CervoMed's insider trading is noteworthy as its drug for Lewy body dementia shows market expectations for new therapies, although challenges in clinical trials remain significant.
- Investor Strategy: Insider buying in biotech stocks is not a buy signal but a research prompt, urging investors to carefully assess company cash flow and market sentiment to avoid losses from market fluctuations.
See More
CervoMed's Neflamapimod Shows Significant Improvement in DLB Patients in Phase 2b Trial
- Clinical Trial Results: CervoMed's Phase 2b RewinD-LB trial demonstrated that neflamapimod significantly improved CDR-SB scores in DLB patients, achieving a 52% reduction compared to placebo over 16 weeks, indicating its potential as a treatment.
- Biomarker Improvement: The treatment group showed a significant reduction in GFAP levels, suggesting that neflamapimod effectively targets neurodegenerative processes, reinforcing its scientific basis as a potential DLB therapy.
- Future Trial Plans: CervoMed is set to initiate a global Phase 3 registrational trial in the second half of 2026 to further validate neflamapimod's efficacy, advancing its path to market.
- Funding Support: The RewinD-LB trial received $21.3 million in NIH funding, covering 43 research sites across the U.S., U.K., and Netherlands, highlighting the broad support and potential impact of this research.
See More
CervoMed Reports New Data on Neflamapimod Clinical Trial, Significant GFAP Reduction
- Significant Biomarker Improvement: At the CTAD conference, CervoMed presented data showing that neflamapimod treatment led to a significant reduction in plasma GFAP levels, achieving a median of -16.0 pg/mL (p<0.0001), indicating the drug's potential in improving neurodegenerative conditions and offering new hope for DLB patients.
- Clinical Effect Correlation: The study revealed a positive correlation between neflamapimod treatment and improvement in CDR-SB scores (r=0.35, p=0.036), which not only validates GFAP as an effective biomarker for DLB disease activity but also strengthens the conclusions regarding neflamapimod's clinical effects.
- Successful Extension Phase: During the 32-week extension phase, patients receiving the new drug batch showed significant reductions in GFAP levels and a notable increase in the A42/40 ratio (p<0.001), suggesting that neflamapimod may act on the underlying disease process in DLB, enhancing the company's confidence as it moves towards the next phase of clinical trials.
- Funding and Research Scale: The RewinD-LB trial was supported by a $21.3 million grant from the NIH, covering 43 research sites across the U.S., U.K., and Netherlands, demonstrating CervoMed's extensive research foundation and future growth potential in the neurodegenerative disease field.
See More
CervoMed's Neflamapimod Significantly Reduces Neurodegeneration Biomarker GFAP
- Clinical Trial Results: CervoMed presented Phase 2b trial results at the CTAD conference showing that neflamapimod significantly reduced plasma GFAP levels, indicating its potential efficacy in neurodegenerative diseases and offering a new treatment option for DLB patients.
- Biomarker Correlation: The study found a positive correlation between the reduction in GFAP levels and clinical improvement (CDR-SB scores), further validating GFAP as an effective biomarker of disease activity in DLB and enhancing confidence in neflamapimod's clinical effects.
- Treatment Continuity: During the 32-week extension, patients receiving the new drug batch showed a median GFAP reduction of 16.0 pg/mL and a significant increase in the Aβ42/40 ratio, demonstrating neflamapimod's potential to improve neuroinflammatory and neurodegenerative profiles.
- Future Development Plans: CervoMed plans to initiate a global Phase 3 clinical trial in the second half of 2026 to further evaluate neflamapimod's efficacy in DLB patients, marking a strategic advancement in the treatment of neurodegenerative diseases.
See More
CervoMed Advances Neflamapimod in Phase 3 Trial for Dementia
- Dose Selection: CervoMed has selected a dosing regimen of 50mg of neflamapimod three times daily for its planned Phase 3 trial to ensure plasma drug concentrations align with those of the clinically effective drug product, thereby enhancing therapeutic efficacy and patient response.
- Manufacturing Process Improvement: The company has developed a new controlled manufacturing process that exclusively produces a stable crystal form of neflamapimod, addressing previous issues with multiple solid-state forms that led to decreased bioavailability, thus improving drug efficacy and safety.
- Clinical Trial Results: In the Phase 2b RewinD-LB trial, neflamapimod demonstrated significant potential to improve cognitive and functional outcomes, particularly in patients without Alzheimer's disease co-pathology, further supporting its scientific validity as a treatment candidate for DLB.
- Future Development Plans: CervoMed plans to initiate a pivotal global Phase 3 trial in the second half of 2026, focusing on DLB patients without AD co-pathology, indicating the company's long-term commitment to this field and highlighting its need for funding.
See More
CervoMed's Neflamapimod Approved for ALS Trials
- Trial Launch: CervoMed's Neflamapimod has been included in the EXPERTS-ALS platform, with the first ALS patient expected to be dosed by the end of 2026, marking a significant advancement in treatments for neurodegenerative diseases.
- Funding Support: The trial costs are funded by the UK National Institute for Health and Care Research and leading motor neuron disease charities, highlighting the commitment to ALS research and support.
- Efficacy Assessment: Neflamapimod will be evaluated in approximately 35 ALS patients over 18-24 weeks, focusing on its impact on the neurodegeneration biomarker NfL, with potential further evaluation expanding to 80 patients.
- Scientific Rationale: Neflamapimod selectively inhibits p38 MAP kinase to reduce neurotoxicity, demonstrating a favorable safety and efficacy profile, potentially offering new treatment hope for ALS patients.
See More
Biotech Insider Buying Signals Strong, Three Companies Draw Attention
- Insider Buying Signals: Summit Therapeutics has recently seen insider purchases, indicating management's confidence in its cancer drug's market potential, which could lead to significant stock price volatility in the future.
- Neurological Drug Development: Annexon also reported insider buying, reflecting confidence in its antibody drugs targeting neurological diseases, despite the high clinical trial risks, the potential for success is substantial.
- Cognitive Disorder Treatment: CervoMed's insider trading is noteworthy as its drug for Lewy body dementia shows market expectations for new therapies, although challenges in clinical trials remain significant.
- Investor Strategy: Insider buying in biotech stocks is not a buy signal but a research prompt, urging investors to carefully assess company cash flow and market sentiment to avoid losses from market fluctuations.
See More
CervoMed's Neflamapimod Shows Significant Improvement in DLB Patients in Phase 2b Trial
- Clinical Trial Results: CervoMed's Phase 2b RewinD-LB trial demonstrated that neflamapimod significantly improved CDR-SB scores in DLB patients, achieving a 52% reduction compared to placebo over 16 weeks, indicating its potential as a treatment.
- Biomarker Improvement: The treatment group showed a significant reduction in GFAP levels, suggesting that neflamapimod effectively targets neurodegenerative processes, reinforcing its scientific basis as a potential DLB therapy.
- Future Trial Plans: CervoMed is set to initiate a global Phase 3 registrational trial in the second half of 2026 to further validate neflamapimod's efficacy, advancing its path to market.
- Funding Support: The RewinD-LB trial received $21.3 million in NIH funding, covering 43 research sites across the U.S., U.K., and Netherlands, highlighting the broad support and potential impact of this research.
See More
CervoMed Reports New Data on Neflamapimod Clinical Trial, Significant GFAP Reduction
- Significant Biomarker Improvement: At the CTAD conference, CervoMed presented data showing that neflamapimod treatment led to a significant reduction in plasma GFAP levels, achieving a median of -16.0 pg/mL (p<0.0001), indicating the drug's potential in improving neurodegenerative conditions and offering new hope for DLB patients.
- Clinical Effect Correlation: The study revealed a positive correlation between neflamapimod treatment and improvement in CDR-SB scores (r=0.35, p=0.036), which not only validates GFAP as an effective biomarker for DLB disease activity but also strengthens the conclusions regarding neflamapimod's clinical effects.
- Successful Extension Phase: During the 32-week extension phase, patients receiving the new drug batch showed significant reductions in GFAP levels and a notable increase in the A42/40 ratio (p<0.001), suggesting that neflamapimod may act on the underlying disease process in DLB, enhancing the company's confidence as it moves towards the next phase of clinical trials.
- Funding and Research Scale: The RewinD-LB trial was supported by a $21.3 million grant from the NIH, covering 43 research sites across the U.S., U.K., and Netherlands, demonstrating CervoMed's extensive research foundation and future growth potential in the neurodegenerative disease field.
See More
CervoMed's Neflamapimod Significantly Reduces Neurodegeneration Biomarker GFAP
- Clinical Trial Results: CervoMed presented Phase 2b trial results at the CTAD conference showing that neflamapimod significantly reduced plasma GFAP levels, indicating its potential efficacy in neurodegenerative diseases and offering a new treatment option for DLB patients.
- Biomarker Correlation: The study found a positive correlation between the reduction in GFAP levels and clinical improvement (CDR-SB scores), further validating GFAP as an effective biomarker of disease activity in DLB and enhancing confidence in neflamapimod's clinical effects.
- Treatment Continuity: During the 32-week extension, patients receiving the new drug batch showed a median GFAP reduction of 16.0 pg/mL and a significant increase in the Aβ42/40 ratio, demonstrating neflamapimod's potential to improve neuroinflammatory and neurodegenerative profiles.
- Future Development Plans: CervoMed plans to initiate a global Phase 3 clinical trial in the second half of 2026 to further evaluate neflamapimod's efficacy in DLB patients, marking a strategic advancement in the treatment of neurodegenerative diseases.
See More
